Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Nguyen

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
European Journal of Clinical Pharmacology|March 27, 2012
Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgeryXavier Delavenne, Paul Zufferey, Philippe Nguyen, et al.
Biomolecules|May 14, 2020
Ticagrelor Prevents Endothelial Cell Apoptosis through the Adenosine Signalling Pathway in the Early Stages of HypoxiaCatherine Feliu, Hélène Peyret, Sylvie Brassart-Pasco, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 27, 2014
Venous thromboembolism: What pharmacists know? What do they need?Jean-Baptiste Rey, Nicolas Jovenin, Pierre Kreit, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 18, 2011
Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generationSonia Ben-Hadj-Khalifa, Nathalie Hézard, Wassim Y Almawi, et al.
Journal of Thrombosis and Thrombolysis|July 6, 2010
Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticlesSonia Ben-Hadj-Khalifa-Kechiche, Nathalie Hezard, Stephane Poitevin, et al.
Cytotherapy|December 5, 2016
Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy productsClaire Tournois, Bernard Pignon, Marie-Antoinette Sevestre, et al.
British Journal of Haematology|June 5, 2003
Biological and clinical features of low-molecular-weight heparin-induced thrombocytopeniaYves Gruel, Claire Pouplard, Philippe Nguyen, et al.
British Journal of Haematology|October 18, 2005
Long-term incubation with IL-4 and IL-10 oppositely modifies procoagulant activity of monocytes and modulates the surface expression of tissue factor and tissue factor pathway inhibitorJérôme Paysant, Claudine Soria, Pascale Cornillet-Lefèbvre, et al.
Canadian Geriatrics Journal : CGJ|October 2, 2018
Feasibility of Implementing an Exercise Program in a Geriatric Assessment Unit: the SPRINT ProgramAndréanne Juneau, Aline Bolduc, Philippe Nguyen, et al.
Thrombosis and Haemostasis|June 12, 2010
Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practiceXavier Delavenne, Paul Zufferey, Denis Baylot, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
European Journal of Clinical Pharmacology|March 27, 2012
Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgeryXavier Delavenne, Paul Zufferey, Philippe Nguyen, et al.
Biomolecules|May 14, 2020
Ticagrelor Prevents Endothelial Cell Apoptosis through the Adenosine Signalling Pathway in the Early Stages of HypoxiaCatherine Feliu, Hélène Peyret, Sylvie Brassart-Pasco, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 27, 2014
Venous thromboembolism: What pharmacists know? What do they need?Jean-Baptiste Rey, Nicolas Jovenin, Pierre Kreit, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 18, 2011
Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generationSonia Ben-Hadj-Khalifa, Nathalie Hézard, Wassim Y Almawi, et al.
Journal of Thrombosis and Thrombolysis|July 6, 2010
Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticlesSonia Ben-Hadj-Khalifa-Kechiche, Nathalie Hezard, Stephane Poitevin, et al.
Cytotherapy|December 5, 2016
Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy productsClaire Tournois, Bernard Pignon, Marie-Antoinette Sevestre, et al.
British Journal of Haematology|June 5, 2003
Biological and clinical features of low-molecular-weight heparin-induced thrombocytopeniaYves Gruel, Claire Pouplard, Philippe Nguyen, et al.
British Journal of Haematology|October 18, 2005
Long-term incubation with IL-4 and IL-10 oppositely modifies procoagulant activity of monocytes and modulates the surface expression of tissue factor and tissue factor pathway inhibitorJérôme Paysant, Claudine Soria, Pascale Cornillet-Lefèbvre, et al.
Canadian Geriatrics Journal : CGJ|October 2, 2018
Feasibility of Implementing an Exercise Program in a Geriatric Assessment Unit: the SPRINT ProgramAndréanne Juneau, Aline Bolduc, Philippe Nguyen, et al.
Thrombosis and Haemostasis|June 12, 2010
Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practiceXavier Delavenne, Paul Zufferey, Denis Baylot, et al.
Pageof 8